

80 mm

PATIENT ALERT CARD

Dabigatran etexilate Hard Capsules dabigatran etexilate

This card should be with you / the caregiver at all times
Make sure to use the latest version

SANDOZ

<u>192 mm</u>

Dear Patient/ Caregiver of a paediatric patient, Your / your child's doctor has initiated treatment with Dabigatran etexilate. In order to use Dabigatran etexilate

safely, please consider the important information in the package leaflet. As this patient alert card contains important information about

your / your child's treatment, this card should be with you / your child at all times to inform healthcare professionals about your / your child's intake of Dabigatran etexilate.


Dabigatran etexilate Information for Patients /Caregivers of paediatric patients About your / your child's treatment

- Dabigatran etexilate thins the blood. It is used to treat existing blood clots or to prevent the formation of dangerous blood clots.
- Follow your / your child's doctor's instructions when taking Dabigatran etexilate. Never skip a dose or stop the intake of Dabigatran etexilate without talking to your / your child's doctor.
- Inform your / your child's doctor about all medicines you / your child are /is currently taking.
- Inform your / your child's doctor about the intake of Dabigatran etexilate before any surgery/invasive procedure.
- Dabigatran etexilate Sandoz capsules can be taken with or without food. The capsules should be swallowed whole with a glass of water. The capsules must not be broken or chewed and the contents must not be emptied from the capsules.

When to seek medical advice

 Taking Dabigatran etexilate may increase the risk of bleeding. Speak to your / your child's doctor immediately if you / your child experience(s) signs and symptoms of bleeding such as: swelling, discomfort, unusual pain or headache, dizziness, paleness, weakness, unusual bruising, nosebleeds, bleeding of gums, unusual long bleeding cuts,

Dimensions: 80 x 192 mm



Variation:	001 - Initial application -Mock ups for National Phase	Tech	Technical Colours:		
Proof no:	001.3		Legend:		
Date prepared:	19/06/2023		Cutting:		
Font size:	8.5 pt				
Fonts:	FuturaCEEF				
Dimensions:	80 x 192 mm				
Technical date					
SKUs:	0000000				
SZ codes:	SZ000000000				
Item codes:	0000000	Cold	Colours:		
Pharma codes:	0000000		Pantone 541		
Novartis data	if applicable:				
Version:	0000000				
Print Proof date:	0000000				
AQWA#:	0000000				
Production site:	0000000				
Technical num:	0000000				
Old Comp num:	0000000		A SANDOZ		

Signature Panel:					
	1				

80 mm
 abnormal menstrual flow or vaginal bleeding, blood in the urine which may be pink or brown, red/black stools, coughing up blood, vomiting blood or coffee ground like material. In case of fall or injury, especially if the head is hit, urgently seek medical advice. Do not stop intake of Dabigatran etexilate without talking to your / your child's doctor, if you / your child experience(s) heartburn, nausea, vomiting, stomach discomfort, bloating or upper abdominal pain. Dabigatran etexilate Information for Healthcare Professionals Dabigatran etexilate Information for Healthcare for thrombin inhibitor). Dabigatran etexilate may need to be stopped in advance of surgical or other invasive procedures. In case of major bleeding events, Dabigatran etexilate must be stopped immediately. A specific reversal agent (idarucizumab)is available for adult patients. The efficacy and safety of the specific reversal agent idarucizumab have not been established in paediatric patients For details and more advice to antagonise the anticoagulant effect of Dabigatran etexilate please refer to the Summary of Product Characteristics of Dabigatran etexilate and idarucizumab. Dabigatran etexilate is mainly eliminated by the kidneys; adequate diuresis must be maintained. Dabigatran etexilate is dialysable. Please complete this section or ask your / your child's doctor to do it.
Name of the patient
Date of birth
Indication for anticoagulation
Dose of Dabigatran etexilate
Date of Revision : Mar 2023

Variation:	001 - Licence app	Tech	nnical Colours:		
Proof no:	001.0		Legend:		
Date prepared:	08/02/2023		Cutting:		
Font size:	8.5 pt				
Fonts:	FuturaCEEF				
Dimensions:	80 x 192 mm				
Technical date	::				
SKUs:	0000000				
SZ codes:	SZ000000000				
Item codes:	0000000	Cold	ours:		
Pharma codes:	0000000		Pantone 541		
Novartis data	if applicable:				
Version:	0000000				
Print Proof date:	0000000				
AQWA#:	0000000				
Production site:	0000000				
Technical num:	0000000				
Old Comp num:	0000000		A SANDOZ		

Signature Panel:				